Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
Enanta Pharmaceuticals (NASDAQ:ENTA) has announced that data from their Phase 2a human challenge study of EDP-323, a first-in-class oral RSV treatment, will be presented at ESCMID Global 2025 in Vienna, Austria. The presentation will showcase results from the study, which were initially announced in September 2024, including new data on respiratory mucus production.
EDP-323 is a non-nucleoside small-molecule inhibitor targeting the RSV polymerase (L-protein). The ePoster presentation, titled 'EDP-323, a First-in-Class, Oral, RSV L-Protein Inhibitor Reduces Disease Severity (Respiratory Mucus Production) and Accelerates Viral Clearance in a Human Viral Challenge Study,' will be presented by Dr. John P. DeVincenzo on April 13, 2025, at 8:30 a.m. CEST.
Enanta Pharmaceuticals (NASDAQ:ENTA) ha annunciato che i dati del loro studio di sfida umana di Fase 2a su EDP-323, un trattamento orale innovativo per il RSV, saranno presentati al ESCMID Global 2025 a Vienna, Austria. La presentazione mostrerà i risultati dello studio, annunciati inizialmente a settembre 2024, inclusi nuovi dati sulla produzione di muco respiratorio.
EDP-323 è un inibitore di piccole molecole non nucleosidico che mira alla polimerasi del RSV (proteina L). La presentazione dell'ePoster, intitolata 'EDP-323, un Inibitore di Classe Innovativa, Orale, della Proteina L del RSV Riduce la Gravità della Malattia (Produzione di Muco Respiratorio) e Accelera la Clearance Virale in uno Studio di Sfida Virale Umana,' sarà presentata dal Dr. John P. DeVincenzo il 13 aprile 2025, alle 8:30 CEST.
Enanta Pharmaceuticals (NASDAQ:ENTA) ha anunciado que los datos de su estudio de desafío humano de Fase 2a sobre EDP-323, un tratamiento oral de primera clase para el RSV, se presentarán en ESCMID Global 2025 en Viena, Austria. La presentación mostrará los resultados del estudio, que se anunciaron inicialmente en septiembre de 2024, incluidos nuevos datos sobre la producción de moco respiratorio.
EDP-323 es un inhibidor de pequeñas moléculas no nucleosídico que se dirige a la polimerasa del RSV (proteína L). La presentación del ePoster, titulada 'EDP-323, un Inhibidor Oral de Clase Innovadora de la Proteína L del RSV Reduce la Severidad de la Enfermedad (Producción de Moco Respiratorio) y Acelera la Eliminación Viral en un Estudio de Desafío Viral Humano,' será presentada por el Dr. John P. DeVincenzo el 13 de abril de 2025, a las 8:30 a.m. CEST.
Enanta Pharmaceuticals (NASDAQ:ENTA)는 EDP-323의 2상 인간 도전 연구 결과가 오스트리아 비엔나에서 열리는 ESCMID Global 2025에서 발표될 것이라고 발표했습니다. 이 발표에서는 2024년 9월에 처음 발표된 연구 결과와 호흡기 점액 생산에 대한 새로운 데이터가 포함됩니다.
EDP-323는 RSV 중합효소(L-단백질)를 표적으로 하는 비뉴클레오사이드 소분자 억제제입니다. 'EDP-323, RSV L-단백질 억제제의 첫 번째 클래스, 호흡기 점액 생산을 감소시키고 인간 바이러스 도전 연구에서 바이러스 제거를 가속화하다'라는 제목의 ePoster 발표는 2025년 4월 13일 오전 8:30 CEST에 John P. DeVincenzo 박사가 발표할 예정입니다.
Enanta Pharmaceuticals (NASDAQ:ENTA) a annoncé que les données de leur étude de défi humain de Phase 2a sur EDP-323, un traitement oral de première classe contre le RSV, seront présentées lors du ESCMID Global 2025 à Vienne, en Autriche. La présentation mettra en avant les résultats de l'étude, qui ont été initialement annoncés en septembre 2024, y compris de nouvelles données sur la production de mucus respiratoire.
EDP-323 est un inhibiteur de petites molécules non nucléosidiques ciblant la polymérase du RSV (protéine L). La présentation de l'ePoster, intitulée 'EDP-323, un Inhibiteur Oral de Première Classe de la Protéine L du RSV Réduit la Sévérité de la Maladie (Production de Mucus Respiratoire) et Accélère l'Élimination Virale dans une Étude de Défi Viral Humain,' sera présentée par le Dr. John P. DeVincenzo le 13 avril 2025 à 8h30 CEST.
Enanta Pharmaceuticals (NASDAQ:ENTA) hat angekündigt, dass die Daten aus ihrer Phase 2a menschlichen Herausforderung Studie zu EDP-323, einer neuartigen oralen RSV-Behandlung, auf der ESCMID Global 2025 in Wien, Österreich, präsentiert werden. Die Präsentation wird Ergebnisse der Studie zeigen, die zunächst im September 2024 bekannt gegeben wurden, einschließlich neuer Daten zur Produktion von Atemwegssekreten.
EDP-323 ist ein nicht-nukleosidischer Kleinstmolekül-Inhibitor, der die RSV-Polymerase (L-Protein) angreift. Die ePoster-Präsentation mit dem Titel 'EDP-323, ein neuartiger oraler RSV L-Protein-Inhibitor reduziert die Schwere der Erkrankung (Atemwegssekretproduktion) und beschleunigt die virale Clearance in einer menschlichen Virus-Herausforderungsstudie,' wird am 13. April 2025 um 8:30 Uhr CEST von Dr. John P. DeVincenzo präsentiert.
- Phase 2a study shows positive results in reducing disease severity and viral clearance
- EDP-323 demonstrates dual benefits: reducing mucus production and accelerating viral clearance
- None.
The oral ePoster presentation will include results from a Phase 2a human challenge study of EDP-323, a first-in-class, oral, non-nucleoside small-molecule inhibitor of the RSV polymerase (L-protein), which were announced in September 2024 and highlight new data on respiratory mucus production.
ePoster Title: “EDP-323, a First-in-Class, Oral, RSV L-Protein Inhibitor Reduces Disease Severity (Respiratory Mucus Production) and Accelerates Viral Clearance in a Human Viral Challenge Study”
ePoster Number: E0289
Abstract Number: 04019
Date and Time: April 13, 2025, 8:30 a.m. CEST/ 2:30 a.m. EDT
Session Location: Arena 1
Session Title: Novel Approaches to Antiviral Therapy
Presenter: John P. DeVincenzo, M.D.
The scientific program for ESCMID Global 2025 can be found here.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (
View source version on businesswire.com: https://www.businesswire.com/news/home/20250408012708/en/
Media and Investor Contact
Jennifer Viera
617-744-3848
jviera@enanta.com
Source: Enanta Pharmaceuticals, Inc.
FAQ
What are the key findings of Enanta's (ENTA) Phase 2a study for EDP-323 in RSV treatment?
When will Enanta Pharmaceuticals (ENTA) present their RSV drug data at ESCMID 2025?
How does Enanta's (ENTA) EDP-323 work against RSV?
What type of study did Enanta (ENTA) conduct for their RSV drug EDP-323?
